Pfizer Limited Stock

Equities

PFIZER

INE182A01018

Pharmaceuticals

Market Closed - NSE India S.E. 07:43:50 2024-07-15 am EDT 5-day change 1st Jan Change
4,940 INR +1.73% Intraday chart for Pfizer Limited +6.79% +15.73%
Sales 2024 21.93B 262M Sales 2025 * 23.51B 281M Capitalization 226B 2.7B
Net income 2024 5.51B 65.97M Net income 2025 * 6.06B 72.47M EV / Sales 2024 8.75 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 9.61 x
P/E ratio 2024
34.8 x
P/E ratio 2025 *
37.3 x
Employees 1,702
Yield 2024 *
1.03%
Yield 2025 *
0.88%
Free-Float 33.1%
More Fundamentals * Assessed data
Dynamic Chart
Pfizer Limited Receives an Order Issued by the Joint Commissioner of Sate Tax, Raipur Division ­ 1: Chhattisgarh CI
Pfizer Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Pfizer Limited Recommends Dividend for the Financial Year Ended March 31, 2024, Payable on or Before September 6, 2024 CI
Pfizer Limited has Received an Order Issued by the Assistant Commissioner, GST & Central Excise, Bhubaneswar-II Division Bhubaneswar CI
Pfizer Limited Receives Order from Deputy Commissioner, Dehradun - Sector 8: Uttarakhand CI
Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer CI
Pfizer Limited Appoints Amit Agarwal as Whole-Time Director, Designated as Executive Director ­Finance CI
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer CI
Pfizer Limited Receives an Order from Joint Commissioner of State Tax Basis the GST Audit Conducted for Uttar Pradesh State for the Financial Year 2018-19 CI
Pfizer Limited Receives an Order from Deputy Commissioner of State Tax Basis the GST Audit Conducted for the Financial Year 2018-19 CI
Pfizer Limited Informs Satyen Amin, Lead - Market Access Tenders His Resignation from Employment, with Effect from March 31, 2024 CI
Pfizer Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Pfizer Ltd. Names CFO MT
Pfizer CFO Retires MT
Pfizer Limited Announces Retirement of Mr. Milind Patil as Chief Financial Officer CI
More news
1 day+1.73%
1 week+6.79%
Current month+9.09%
1 month+2.30%
3 months+18.83%
6 months+13.63%
Current year+15.73%
More quotes
1 week
4 585.00
Extreme 4585
5 050.00
1 month
4 501.00
Extreme 4501
5 050.00
Current year
3 950.00
Extreme 3950
5 050.00
1 year
3 782.15
Extreme 3782.15
5 050.00
3 years
3 408.00
Extreme 3408
6 175.00
5 years
2 792.25
Extreme 2792.25
6 175.00
10 years
1 320.00
Extreme 1320
6 175.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 23-04-02
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - -
Members of the board TitleAgeSince
Chairman 71 99-12-06
Director/Board Member 74 12-05-20
Director/Board Member 64 15-02-13
More insiders
Date Price Change Volume
24-07-15 4,940 +1.73% 217,710
24-07-12 4,856 -1.91% 28,498
24-07-11 4,951 -1.35% 31,982
24-07-10 5,019 +6.52% 229,239
24-07-09 4,712 +2.67% 30,704

Delayed Quote NSE India S.E., July 15, 2024 at 07:43 am EDT

More quotes
Pfizer Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The Company has its own manufacturing facility at Goa. The Company has various independent contract/third party manufacturers based across India. Its product portfolio includes vaccine, anti-infectives, cardiac, pain, maternal nutrition, gastrointestinal, contraceptives, anti-inflammatory, nutrition and immunity, and respiratory. The Company's vaccine business is focused on Prevenar 13, a pneumococcal conjugate vaccine that is administered to infants who are six weeks and older as part of primary vaccination, toddlers, adolescents, adults, and elderly population. Its inflammation and immunology portfolio includes two advanced therapies, which cater to patients suffering from diseases related to chronic immune system such as rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, psoriasis and ulcerative colitis.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. PFIZER Stock